Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges
Cell Chemical Biology · 2024-01 · 31 (1) · 125-138
DOI: 10.1016/j.chembiol.2023.09.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Chemical Biology, 2024-01. Verfasst von Cristina R Hofman und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9041, USA. Hauptthemen laut MEDLINE: RNA, Oligonucleotides. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Welch Foundation, National Institutes of Health.
Abstract (Originalsprache)
Synthetic antisense oligonucleotides (ASOs) and duplex RNAs (dsRNAs) are an increasingly successful strategy for drug development. After a slow start, the pace of success has accelerated since the approval of Spinraza (nusinersen) in 2016 with several drug approvals. These accomplishments have been achieved even though oligonucleotides are large, negatively charged, and have little resemblance to traditional small-molecule drugs-a remarkable achievement of basic and applied science. The goal of this review is to summarize the foundation underlying recent progress and describe ongoing research programs that may increase the scope and impact of oligonucleotide therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9041, USA.
- The Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9041, USA. Electronic address: david.corey@utsouthwestern.edu.
Förderung
- NIGMS NIH HHS
- Welch Foundation
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Hofman, C. R., & Corey, D. R. (2024). Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges. Cell Chemical Biology, 31(1), 125-138. https://doi.org/10.1016/j.chembiol.2023.09.005
Vancouver
Hofman CR, Corey DR. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges. Cell Chemical Biology. 2024;31(1):125-138. doi:10.1016/j.chembiol.2023.09.005
BibTeX
@article{Hofman2024,
author = {Hofman, Cristina R and Corey, David R},
title = {Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges},
journal = {Cell Chemical Biology},
year = {2024},
volume = {31},
number = {1},
pages = {125--138},
doi = {10.1016/j.chembiol.2023.09.005}
}
EUVIMED